-+ 0.00%
-+ 0.00%
-+ 0.00%

NRx advances robotic TMS plus D-cycloserine neuroplastic therapy for military, responders

PUBT·04/15/2026 11:02:47
Listen to the news
NRx advances robotic TMS plus D-cycloserine neuroplastic therapy for military, responders
  • NRx Pharmaceuticals formed NRx Defense Systems to develop combined neuroplastic therapy pairing D-cycloserine (NRX-101) with robotic-enabled transcranial magnetic stimulation for depression and PTSD in military and first-responder settings.
  • Program targets forward-deployable, AI-enabled treatment delivery designed to reduce reliance on specialized medical staff, addressing force-readiness constraints tied to antidepressant use.
  • Prototype development will run with Zeta Surgical, using its FDA 510(k)-cleared AI neuronavigation platform for TMS navigation cleared in October 2025.
  • NRx expects to unveil prototype system at Clinical TMS Society annual meeting in Boston from June 4-6, 2026.
  • NRx Defense Systems leadership includes President Dennis McBride, supported by Chief Medical Innovation Officer Joshua Brown, with Chairman Jonathan Javitt overseeing subsidiary.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150700PRIMZONEFULLFEED9690156) on April 15, 2026, and is solely responsible for the information contained therein.